Bruxism, temporomandibular disorders and consequences in patients with Parkinson*s disease

Completed

Conditions: tandheelkundig
temporomandibular disorders
bruxism
10028302
10028037

Registration Number: NL-OMON49742

Lead Sponsor: niversiteit van Amsterdam

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 235

Inclusion Criteria

- Patients who visit the outpatient clinic for movement disorders of the VUmc
hospital with (presumable) PD.
- Adults (>18 years old)

Exclusion Criteria

- Children or adolescents (<18 years old)
- Patients with a pacemaker (only excluded for using GrindCare® GC3+)
- Patients who do not fulfil the clinical diagnostic criteria for PD
- Patients with atypical parkinsonian syndromes
- Montreal Cognitive Assessment (MoCA) score < 21

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- (Definite) bruxism diagnosis<br /><br>- TMD diagnosis (according to the Diagnostic Criteria for TMD; DC/TMD)<br /><br>- Levodopa equivalent daily dose (LEDD)<br /><br>- Pain intensity (GCPS)<br /><br>- Tooth wear screening (TWES)<br /><br>- Depression (BDI-ii)<br /><br>- Anxiety (PASS)<br /><br>- Stress (PHQ-15)<br /><br>- Cognitive function (PD-CRFS and MoCA)<br /><br>- Disease stage (Hoehn & Yahr)<br /><br>- Disease severity (Unified Parkinson*s Disease Rating Scale; UPDRS III)<br /><br>- SCOPA-SLEEP scale </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Salivary flow, pH and buffer capacity of saliva<br /><br>- Tooth wear screening index (TWES)<br /><br>- Brain imaging, for example presynaptic dopaminergic loss visualized with<br /><br>DAT-SPECT (if applicable) </p><br>